Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

696 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase I/II study of GLIF combination chemotherapy for taxane/platinum-refractory/resistant endometrial cancer (GOGO-EM2).
Tanaka Y, Ueda Y, Nakagawa S, Matsuzaki S, Kobayashi E, Shiki Y, Nishio Y, Takemura M, Yamamoto T, Sawada K, Tomimatsu T, Yoshino K, Kimura T. Tanaka Y, et al. Among authors: nishio y. Cancer Chemother Pharmacol. 2018 Oct;82(4):585-592. doi: 10.1007/s00280-018-3648-y. Epub 2018 Jul 20. Cancer Chemother Pharmacol. 2018. PMID: 30030584 Free PMC article. Clinical Trial.
Chemotherapy for endometrial carcinoma (GOGO-EM1 study): TEC (paclitaxel, epirubicin, and carboplatin) is an effective remission-induction and adjuvant therapy.
Egawa-Takata T, Ueda Y, Kuragaki C, Miyake T, Miyatake T, Fujita M, Yoshino K, Nakashima R, Okazawa M, Tsutsui T, Morishige K, Kimura T, Yamasaki M, Nishizaki T, Nagamatsu M, Ito K, Asada M, Ogita K, Wakimoto A, Yamamoto T, Nishio Y, Enomoto T. Egawa-Takata T, et al. Among authors: nishio y. Cancer Chemother Pharmacol. 2011 Dec;68(6):1603-10. doi: 10.1007/s00280-011-1638-4. Epub 2011 May 17. Cancer Chemother Pharmacol. 2011. PMID: 21584840 Clinical Trial.
A phase II study of combination chemotherapy using docetaxel and irinotecan for TC-refractory or TC-resistant ovarian carcinomas (GOGO-OV2 study) and for primary clear or mucinous ovarian carcinomas (GOGO-OV3 Study).
Ueda Y, Miyatake T, Nagamatsu M, Yamasaki M, Nishio Y, Yoshino K, Fujita M, Tsutsui T, Enomoto T, Kimura T. Ueda Y, et al. Among authors: nishio y. Eur J Obstet Gynecol Reprod Biol. 2013 Sep;170(1):259-63. doi: 10.1016/j.ejogrb.2013.06.035. Epub 2013 Jul 20. Eur J Obstet Gynecol Reprod Biol. 2013. PMID: 23880598 Clinical Trial.
Efficacy of raloxifene hydrochloride for the prevention of health care problems in patients who undergo surgery for endometrial cancer: a multicenter randomized clinical trial.
Nakamura K, Sawada K, Sugiyama M, Mabuchi S, Hisamatsu T, Nishio Y, Ito K, Kimura T, Kamiura S, Morishige K. Nakamura K, et al. Among authors: nishio y. Int J Gynecol Cancer. 2015 Feb;25(2):288-95. doi: 10.1097/IGC.0000000000000333. Int J Gynecol Cancer. 2015. PMID: 25569817 Clinical Trial.
Adjuvant Chemotherapy for Endometrial Cancer (ACE) trial: A randomized phase II study for advanced endometrial carcinoma.
Egawa-Takata T, Ueda Y, Ito K, Hori K, Tadahiro S, Nagasawa T, Nishio S, Ushijima K, Koji N, Enomoto T, Kikuchi A, Honma S, Oishi T, Shimada M, Takei Y, Fujiwara H, Tanabe H, Okamoto A, Nishio Y, Yamada T, Kimura T. Egawa-Takata T, et al. Among authors: nishio y, nishio s. Cancer Sci. 2022 May;113(5):1693-1701. doi: 10.1111/cas.15310. Epub 2022 Mar 10. Cancer Sci. 2022. PMID: 35218673 Free PMC article. Clinical Trial.
Vascular endothelial growth factor is a promising therapeutic target for the treatment of clear cell carcinoma of the ovary.
Mabuchi S, Kawase C, Altomare DA, Morishige K, Hayashi M, Sawada K, Ito K, Terai Y, Nishio Y, Klein-Szanto AJ, Burger RA, Ohmichi M, Testa JR, Kimura T. Mabuchi S, et al. Among authors: nishio y. Mol Cancer Ther. 2010 Aug;9(8):2411-22. doi: 10.1158/1535-7163.MCT-10-0169. Epub 2010 Jul 27. Mol Cancer Ther. 2010. PMID: 20663925 Free PMC article.
Peripheral quantitative computed tomography (pQCT) is useful for monitoring bone mineral density of the patients who receive hormone replacement therapy.
Sawada K, Morishige K, Ohmichi M, Nishio Y, Yamamoto T, Hayakawa J, Mabuchi S, Isobe A, Sasaki H, Sakata M, Tasaka K, Murata Y. Sawada K, et al. Among authors: nishio y. Maturitas. 2007 Apr 20;56(4):343-9. doi: 10.1016/j.maturitas.2006.08.006. Epub 2006 Sep 28. Maturitas. 2007. PMID: 17010541 Clinical Trial.
696 results